CO7151509A2 - Difluoro-hexahidro-ciclopentaoxacinilos y difluoro-hexahidro-benzooxacinilos como inhibidores de bace1 - Google Patents

Difluoro-hexahidro-ciclopentaoxacinilos y difluoro-hexahidro-benzooxacinilos como inhibidores de bace1

Info

Publication number
CO7151509A2
CO7151509A2 CO14271199A CO14271199A CO7151509A2 CO 7151509 A2 CO7151509 A2 CO 7151509A2 CO 14271199 A CO14271199 A CO 14271199A CO 14271199 A CO14271199 A CO 14271199A CO 7151509 A2 CO7151509 A2 CO 7151509A2
Authority
CO
Colombia
Prior art keywords
difluoro
hexahydro
cyclopentaoxacinyls
benzooxacinyls
bace1 inhibitors
Prior art date
Application number
CO14271199A
Other languages
English (en)
Inventor
Hans Hilpert
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CO7151509A2 publication Critical patent/CO7151509A2/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D265/00Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/041,3-Oxazines; Hydrogenated 1,3-oxazines
    • C07D265/121,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención proporciona difluoro-ciclopentaoxacinilos y difluoroenzooxacinilos de fórmula (I) que tienen actividad inhibidora BACE1, su fabricación, composiciones farmacéuticas que los contienen y su uso como sustancias terapéuticamente activas. Los compuestos activos de la presente invención son útiles en el tratamiento terapéutico y / o profiláctico de, por ejemplo la enfermedad de Alzheimer.
CO14271199A 2012-06-26 2014-12-10 Difluoro-hexahidro-ciclopentaoxacinilos y difluoro-hexahidro-benzooxacinilos como inhibidores de bace1 CO7151509A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP12173690 2012-06-26

Publications (1)

Publication Number Publication Date
CO7151509A2 true CO7151509A2 (es) 2014-12-29

Family

ID=48672630

Family Applications (1)

Application Number Title Priority Date Filing Date
CO14271199A CO7151509A2 (es) 2012-06-26 2014-12-10 Difluoro-hexahidro-ciclopentaoxacinilos y difluoro-hexahidro-benzooxacinilos como inhibidores de bace1

Country Status (22)

Country Link
US (1) US9181232B2 (es)
EP (1) EP2864324B1 (es)
JP (1) JP6251257B2 (es)
KR (1) KR20150023450A (es)
CN (1) CN104470915B (es)
AU (1) AU2013283524B2 (es)
BR (1) BR112014029742A2 (es)
CA (1) CA2872181A1 (es)
CL (1) CL2014003325A1 (es)
CO (1) CO7151509A2 (es)
CR (1) CR20140528A (es)
EA (1) EA025273B1 (es)
HK (1) HK1206344A1 (es)
IL (1) IL236138A (es)
MA (1) MA37763B1 (es)
MX (1) MX2014014937A (es)
NZ (1) NZ702253A (es)
PE (1) PE20142450A1 (es)
PH (1) PH12014502623B1 (es)
SG (1) SG11201407576YA (es)
UA (1) UA113309C2 (es)
WO (1) WO2014001228A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ589590A (en) 2008-06-13 2012-05-25 Shionogi & Co Sulfur-containing heterocyclic derivative having beta-secretase-inhibiting activity
US8999980B2 (en) 2009-12-11 2015-04-07 Shionogi & Co., Ltd. Oxazine derivatives
JP2016501827A (ja) 2012-10-24 2016-01-21 塩野義製薬株式会社 Bace1阻害作用を有するジヒドロオキサジンまたはオキサゼピン誘導体
AU2014223334C1 (en) 2013-03-01 2018-10-18 Amgen Inc. Perfluorinated 5,6-dihydro-4H-1,3-oxazin-2-amine compounds as beta-secretase inhibitors and methods of use
MX2015011618A (es) 2013-03-08 2015-12-17 Amgen Inc Compuestos de 1,3-oxazin-2-amina fusionados con ciclopropilo perfluorado como inhibidores de beta-secretasa y metodos de uso.
TW201623295A (zh) 2014-04-11 2016-07-01 塩野義製藥股份有限公司 具有bace1抑制活性之二氫噻及二氫衍生物
CA2957544C (en) 2014-08-08 2023-01-24 Amgen Inc. Cyclopropyl fused thiazin-2-amine compounds as beta-secretase inhibitors and methods of use
SG11201707050VA (en) 2015-03-20 2017-10-30 Hoffmann La Roche Bace1 inhibitors
JP7353708B2 (ja) * 2018-04-27 2023-10-02 塩野義製薬株式会社 選択的bace1阻害活性を有するテトラヒドロピラノオキサジン誘導体

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2010047372A1 (ja) 2008-10-22 2012-03-22 塩野義製薬株式会社 Bace1阻害活性を有する2−アミノピリミジン−4−オンおよび2−アミノピリジン誘導体
GB0912778D0 (en) * 2009-07-22 2009-08-26 Eisai London Res Lab Ltd Fused aminodihydro-oxazine derivatives
UA103272C2 (uk) * 2009-12-11 2013-09-25 Ф. Хоффманн-Ля Рош Аг 2-аміно-5,5-дифтор-5,6-дигідро-4h-оксазини як інгібітори bace1 і/або bace2
US8999980B2 (en) * 2009-12-11 2015-04-07 Shionogi & Co., Ltd. Oxazine derivatives

Also Published As

Publication number Publication date
EP2864324B1 (en) 2018-03-28
CA2872181A1 (en) 2014-01-03
IL236138A0 (en) 2015-02-01
EA025273B1 (ru) 2016-12-30
SG11201407576YA (en) 2015-03-30
CN104470915B (zh) 2019-07-26
EA201590066A1 (ru) 2015-04-30
JP6251257B2 (ja) 2017-12-20
KR20150023450A (ko) 2015-03-05
CL2014003325A1 (es) 2015-04-24
UA113309C2 (xx) 2017-01-10
EP2864324A1 (en) 2015-04-29
PH12014502623A1 (en) 2015-01-21
HK1206344A1 (en) 2016-01-08
BR112014029742A2 (pt) 2017-06-27
AU2013283524B2 (en) 2017-03-30
MA37763B1 (fr) 2017-05-31
US9181232B2 (en) 2015-11-10
IL236138A (en) 2016-10-31
CR20140528A (es) 2015-01-12
PH12014502623B1 (en) 2015-01-21
MA37763A1 (fr) 2016-08-31
PE20142450A1 (es) 2015-01-28
JP2015521640A (ja) 2015-07-30
NZ702253A (en) 2016-06-24
MX2014014937A (es) 2015-03-09
US20150133440A1 (en) 2015-05-14
AU2013283524A1 (en) 2014-11-13
WO2014001228A1 (en) 2014-01-03
CN104470915A (zh) 2015-03-25

Similar Documents

Publication Publication Date Title
CR20130588A (es) Halogenoalquil-1,3-oxazinas como inhibidores de la bace1 y/o bace 2
ECSP13013024A (es) 1,3-oxazinas como inhibidores de bace1 y/o bace2
CR20130432A (es) 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2
ECSP13013048A (es) Spiro-[1,3]-oxacinas y spiro-[1,4]-oxacepinas como inhibidores
CO7151509A2 (es) Difluoro-hexahidro-ciclopentaoxacinilos y difluoro-hexahidro-benzooxacinilos como inhibidores de bace1
MX2015008957A (es) Fluoro-[1,3]oxazinas como inhibidores de beta-secretasa 1 (bace1).
UA113538C2 (xx) Фторметил-5,6-дигідро-4h-$1,3]оксазини
CL2016002072A1 (es) 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer
PE20121617A1 (es) Derivados de oxazina como inhibidores de bace
CO7131369A2 (es) 5-amino[1,4]tiazinas como inhibidores de bace1
PH12015502365B1 (en) Bace1 inhibitors
DOP2015000170A (es) Compuestos químicos
MX2013014194A (es) 1,3-tiazepinas fusionadas a ciclopropilo como inhibidores de beta-secretasa 1 (bace) y/o beta-secretasa 2 (bace 2).
CL2017002229A1 (es) Inhibidores de bace1.
MX2016006906A (es) 5-aril-1-imino-1-oxo-[1,2,4]tiadiazinas.
MX2016016061A (es) 2,2,2-trifluoroetil-tiadiazinas.